Clinical Experience

: Clinical Experience

Print
Share
Bookmark
Text Size:

For appropriate patients with type 2 diabetes...

Start with the power of JANUMET

Starting Therapy

In a study of patients uncontrolled with diet and exercise at 24 weeks, JANUMET delivered powerful A1C reductions, got nearly twice as many patients to goal, and provided significantly greater reductions in both PPG and FPG vs metformin alone.¹

Goal Attainment

A1C Reductions
(Primary End Point)

FPG & PPG Reductions

Data in Higher Baseline A1C Patients (median baseline A1C=9.7%)

In a study of patients uncontrolled with diet and exercise at 18 weeks, JANUMET delivered powerful A1C reductions, with nearly 1 in 2 patients achieving ADA goal and significantly greater reductions in FPG vs metformin alone.²

A1C Reductions

Goal Attainment

FPG Reductions

Sustained A1C Reductions Over 2 Years

In extension-study participants on 104 weeks of initial therapy, JANUMET delivered sustained A1C reductions over 2 years.³

Click to View

Clinical Studies

Clinical studies conducted with sitagliptin + metformin.

Click to View

Selected Important Risk Information

JANUMET is contraindicated in patients with renal disease or renal dysfunction (serum creatinine levels >1.5 mg/dL in males and >1.4 mg/dL in females) or abnormal creatinine clearance; acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma; or history of a serious hypersensitivity reaction to JANUMET or sitagliptin (one of the components of JANUMET), such as anaphylaxis or angioedema.

Temporarily discontinue JANUMET in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function. Avoid use in patients with hepatic disease. Temporarily discontinue for intercurrent serious conditions, infection, or surgery.

Please read the Boxed Warning about lactic acidosis.

Important Information

JANUMET^® (sitagliptin/metformin HCI) tablets is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

JANUMET should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUMET.

Before prescribing JANUMET^® (sitagliptin/metformin HCl) tablets, please read the Prescribing Information, including the Boxed Warning about lactic acidosis. The Medication Guide also is available.

References 1. Goldstein BJ, Feinglos MN, Lunceford JK, et al; for Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–1987. Dr. Goldstein is currently an employee at Merck, but was in academia at the time of publication. 2. Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(7):644–652. 3. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(5):442–451.

This site is intended for health care professionals of the United States, its territories, and Puerto Rico.

Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

DIAB-1050515-0000 12/12

5.

Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package DIAB-1003569-0005.
9.

Goldstein BJ, Feinglos MN, Lunceford JK, et al; for Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–1987. Dr. Goldstein is currently an employee at Merck, but was in academia at the time of publication.
56.

Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package DIAB-1023729-0000.
57.

Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(7):644–652.

Close

^5.

Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package DIAB-1003569-0005.

Close

^9.

Goldstein BJ, Feinglos MN, Lunceford JK, et al; for Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–1987. Dr. Goldstein is currently an employee at Merck, but was in academia at the time of publication.

Close

^56.

Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package DIAB-1023729-0000.

Close

^57.

Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(7):644–652.